Troluce Capital Advisors LLC acquired a new position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 712,254 shares of the company's stock, valued at approximately $7,187,000. Roivant Sciences comprises about 2.1% of Troluce Capital Advisors LLC's holdings, making the stock its 12th biggest holding. Troluce Capital Advisors LLC owned about 0.10% of Roivant Sciences at the end of the most recent reporting period.
Several other institutional investors have also modified their holdings of ROIV. Parallel Advisors LLC lifted its position in shares of Roivant Sciences by 80.5% during the 1st quarter. Parallel Advisors LLC now owns 2,485 shares of the company's stock worth $25,000 after buying an additional 1,108 shares during the last quarter. UMB Bank n.a. lifted its position in shares of Roivant Sciences by 112.7% during the 1st quarter. UMB Bank n.a. now owns 4,143 shares of the company's stock worth $42,000 after buying an additional 2,195 shares during the last quarter. Russell Investments Group Ltd. lifted its position in shares of Roivant Sciences by 94.8% during the 1st quarter. Russell Investments Group Ltd. now owns 4,588 shares of the company's stock worth $46,000 after buying an additional 2,233 shares during the last quarter. Fifth Third Bancorp lifted its position in shares of Roivant Sciences by 59.3% during the 1st quarter. Fifth Third Bancorp now owns 5,118 shares of the company's stock worth $52,000 after buying an additional 1,905 shares during the last quarter. Finally, GAMMA Investing LLC lifted its position in shares of Roivant Sciences by 83.0% during the 1st quarter. GAMMA Investing LLC now owns 6,493 shares of the company's stock worth $66,000 after buying an additional 2,945 shares during the last quarter. Hedge funds and other institutional investors own 64.76% of the company's stock.
Roivant Sciences Price Performance
Shares of Roivant Sciences stock opened at $11.93 on Monday. The firm's fifty day simple moving average is $11.49 and its 200-day simple moving average is $10.97. The stock has a market capitalization of $8.15 billion, a price-to-earnings ratio of -17.04 and a beta of 1.15. Roivant Sciences Ltd. has a 12 month low of $8.73 and a 12 month high of $13.06.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last announced its earnings results on Thursday, May 29th. The company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.15). The business had revenue of $7.57 million during the quarter, compared to analyst estimates of $62.17 million. Roivant Sciences had a negative net margin of 2,111.79% and a negative return on equity of 15.90%. During the same period in the previous year, the firm earned ($0.23) earnings per share. Analysts anticipate that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.
Wall Street Analyst Weigh In
Several analysts have recently weighed in on the stock. HC Wainwright restated a "buy" rating and set a $18.00 price objective on shares of Roivant Sciences in a research report on Wednesday, June 18th. The Goldman Sachs Group raised shares of Roivant Sciences to a "strong-buy" rating and set a $19.00 target price on the stock in a report on Thursday, July 10th. Two analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, Roivant Sciences presently has an average rating of "Buy" and a consensus price target of $16.50.
Check Out Our Latest Stock Report on ROIV
Insider Buying and Selling at Roivant Sciences
In other Roivant Sciences news, major shareholder Vivek Ramaswamy sold 577,007 shares of the business's stock in a transaction on Friday, June 20th. The shares were sold at an average price of $11.46, for a total value of $6,612,500.22. Following the transaction, the insider directly owned 37,284,108 shares of the company's stock, valued at approximately $427,275,877.68. The trade was a 1.52% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Eric Venker sold 566,278 shares of the business's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $11.22, for a total transaction of $6,353,639.16. Following the completion of the transaction, the chief operating officer directly owned 1,462,223 shares in the company, valued at $16,406,142.06. This represents a 27.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 2,756,781 shares of company stock worth $31,362,243 over the last three months. 10.80% of the stock is currently owned by corporate insiders.
About Roivant Sciences
(
Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Featured Articles
Want to see what other hedge funds are holding ROIV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
